AIM ImmunoTech Announces Debt-to-Equity Conversion Settling $1.22M Note

What Happened

• AIM ImmunoTech Inc. announced it entered into five exchange agreements with Streeterville Capital, LLC between August 31 and September 3, 2026 to convert outstanding debt into equity.
• Approximately $1,224,341 under a Promissory Note dated February 16, 2024 was converted into 5,065,840 shares of common stock at an average conversion price of about $0.24 per share. As of September 3, 2026, the Promissory Note is satisfied in full.

Key Details

• Lender: Streeterville Capital, LLC.
• Conversion period: August 31, 2026 through September 3, 2026.
• Amount converted: ~$1,224,341 into 5,065,840 shares (avg. $0.24/share).
• Stockholder approval: Conversion or other satisfaction of the Promissory Note was approved at a special meeting on July 15, 2026 under NYSE American Company Guide Sections 713(a) and 713(b).
• Exhibit filed: Form of Exchange Agreement is included as Exhibit 10.1 to the 8-K.

Why It Matters

• The company eliminated a material outstanding debt obligation, removing the related repayment obligation and any associated interest requirements under that Promissory Note.
• Investors should note the issuance of 5,065,840 new shares — this increases shares outstanding and is a dilutive event for existing shareholders.
• The transaction was completed with prior shareholder approval and is documented in the filed exchange agreements, reducing counterparty credit risk tied to that specific note.